Trial Profile
A Comparative Bioavailability Study to Compare the Pharmacokinetic (PK)and Pharmacodynamic (PD) Effects of Fluticasone Propionate and Salmeterol Delivered by Fluticasone Propionate/ Salmeterol Combination in a Capsule-based Inhaler and a Multi-dose Dry Powder Inhaler, in Moderate Asthma Patients and Moderate to Severe COPD Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jul 2023
Price :
$35
*
At a glance
- Drugs Salmeterol/fluticasone propionate (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 23 Dec 2011 New trial record